{
  "docId": "019de075-c3df-7648-ab3f-403a3e018886",
  "docSlug": "132267474e075f06292187997a008f90",
  "documentTitle": "OmniAb | Investor Presentation Deck | 35 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 35,
  "pageCount": 35,
  "prevPage": 34,
  "nextPage": null,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 28,
  "notes": "The slide uses a Gantt-style visualization to show the progress of drug candidates through clinical phases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c3df-7648-ab3f-403a3e018886/35",
  "deckHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886",
  "deckJsonHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886.json",
  "deckAnchorHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886#slide-35",
  "components": [
    {
      "bbox": {
        "h": 0.72,
        "w": 0.45,
        "x": 0.51,
        "y": 0.16
      },
      "kind": "chart",
      "text": "Clinical phase progress bars",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1637201d-7104-4035-abd9-828d30ca7f89",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.04,
        "y": 0.96
      },
      "kind": "legend",
      "text": "Indicates program with fully paid license from OMT, prior to acquisition. Programs discovered by Teneobio under a fully paid license. Future programs discovered under license agreement are subject to downstream economics.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a64f27f-ccbf-4c7d-bc1d-15e0ddba61ee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.04,
        "y": 0.93
      },
      "kind": "paragraph",
      "text": "Notes: Most advanced status for each program shown. Zimberelimab and Sugemalimab are approved and marketed in China. Teclistamab is approved and marketed in the US and EU with $35M launch milestones paid.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d1bf99c-8059-42e6-92c2-1157fdaacf99",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.04,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Animal launch year: OmniRat 2012; OmniMouse 2014; OmniFlic 2014; OmniChicken 2016; OmniClic 2019; OmniTaur 2020",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be5b8303-9a10-431e-820d-d6ba46215564",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.72,
        "w": 0.92,
        "x": 0.04,
        "y": 0.16
      },
      "kind": "table",
      "text": "Partner, Program, Source Animal, Therapy Area, Target, Phase 1, Phase 2, Phase 3, Registration, Approved",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f189f45d-e464-4b13-87f0-eb26f9048342",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Approved, Under Regulatory Review and Clinical-Stage Partner Pipeline",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76db1bb1-8fa5-482c-897d-291e6a1fc429",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "0f7cd6c1-c326-4a9c-be64-27704eec67e8",
      "evidence": "chart/bar-horizontal: Clinical phase progress bars",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "39cc9033-e8d0-4245-9739-8ccc4e4b0fb0",
      "evidence": "Horizontal bars representing clinical phase progress over time/stages",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 35,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1674fffb-efec-427e-b437-66fc0c0fd01e",
      "evidence": "The document presents the potential consequences of not investing in effective discovery technology.",
      "position": 0,
      "objective": "Highlight the importance of investing in OmniAb's technology to drive growth and success in the biotech industry.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}